Heterosexual contact is now the primary route of transmission for HIV worldwide. This study
is a phase 3 trial designed to determine the effectiveness and safety of the 1.0% C31G
(SAVVY) vaginal gel for the prevention of male-to-female transmission of HIV among women at
high risk.
Phase:
Phase 3
Details
Lead Sponsor:
Biosyn
Collaborators:
FHI 360 United States Agency for International Development (USAID)